Deciphera Pharmaceuticals (NASDAQ:DCPH) was upgraded by stock analysts at BidaskClub from a “sell” rating to a “hold” rating in a report released on Tuesday.

A number of other research firms have also commented on DCPH. JMP Securities lifted their target price on Deciphera Pharmaceuticals to $65.00 and gave the stock an “outperform” rating in a report on Tuesday, June 19th. B. Riley lowered Deciphera Pharmaceuticals from a “buy” rating to a “neutral” rating and set a $43.00 target price for the company. in a report on Tuesday, June 19th. SunTrust Banks initiated coverage on Deciphera Pharmaceuticals in a report on Thursday, July 5th. They issued a “buy” rating for the company. Leerink Swann initiated coverage on Deciphera Pharmaceuticals in a report on Monday. They issued an “underperform” rating for the company. Finally, Zacks Investment Research raised Deciphera Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Monday, June 4th. One research analyst has rated the stock with a sell rating, four have assigned a hold rating and ten have given a buy rating to the stock. The company presently has a consensus rating of “Buy” and an average price target of $50.10.

Deciphera Pharmaceuticals stock opened at $39.92 on Tuesday. The firm has a market capitalization of $1.47 billion and a price-to-earnings ratio of -13.35. Deciphera Pharmaceuticals has a 12 month low of $15.15 and a 12 month high of $45.61. The company has a debt-to-equity ratio of 0.05, a current ratio of 18.44 and a quick ratio of 18.44.

Deciphera Pharmaceuticals (NASDAQ:DCPH) last posted its earnings results on Tuesday, August 7th. The company reported ($0.65) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.68) by $0.03. equities research analysts forecast that Deciphera Pharmaceuticals will post -2.59 earnings per share for the current year.

Several institutional investors and hedge funds have recently modified their holdings of DCPH. Bank of America Corp DE grew its holdings in shares of Deciphera Pharmaceuticals by 316.1% in the second quarter. Bank of America Corp DE now owns 2,609 shares of the company’s stock worth $103,000 after acquiring an additional 1,982 shares during the period. SG Americas Securities LLC bought a new stake in Deciphera Pharmaceuticals during the first quarter valued at about $152,000. New York State Common Retirement Fund grew its holdings in Deciphera Pharmaceuticals by 37.5% during the first quarter. New York State Common Retirement Fund now owns 9,900 shares of the company’s stock valued at $198,000 after purchasing an additional 2,700 shares during the period. Trexquant Investment LP bought a new stake in Deciphera Pharmaceuticals during the second quarter valued at about $203,000. Finally, Rhumbline Advisers bought a new stake in Deciphera Pharmaceuticals during the second quarter valued at about $301,000. 53.53% of the stock is owned by institutional investors.

Deciphera Pharmaceuticals Company Profile

Deciphera Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response of various cancer therapies. The company's lead drug candidate is DCC-2618, which is in Phase III trial for the treatment of gastrointestinal stromal tumors; and that is in Phase I trial for treating advanced systemic mastocytosis, gliomas, and other solid tumors.

Read More: Buyback For Investors Defined

Analyst Recommendations for Deciphera Pharmaceuticals (NASDAQ:DCPH)

Receive News & Ratings for Deciphera Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Deciphera Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.